Saroglitazar

Saroglitazar is a novel, once-daily oral agent used for the treatment of dyslipidemia in adult patients. It is a peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist that works by modulating the lipid metabolism in the body. By targeting both PPAR alpha and gamma receptors, it helps to reduce triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels, while having a neutral or minimal effect on low-density lipoprotein cholesterol (LDL-C) levels.
The primary indication for Saroglitazar is in patients with mixed dyslipidemia, which is characterized by high triglyceride levels, low HDL-C levels, and variable LDL-C levels. It is commonly prescribed for patients who are at a high risk of cardiovascular diseases and have not achieved adequate lipid control with diet and lifestyle modifications, or with other lipid-lowering therapies.
In addition to its lipid-modifying effects, Saroglitazar has been shown to possess anti-inflammatory and anti-oxidant properties, which can potentially help reduce the risk of cardiovascular complications. Monitor liver function tests during the course of treatment, as Saroglitazar may cause elevation in liver enzymes in some patients. It should be used with caution in patients with pre-existing liver diseases, as well as in those with impaired renal function.
Saroglitazar provides an additional treatment option for healthcare professionals in managing patients with dyslipidemia who have not achieved adequate lipid control with other therapies. It plays a vital role in reducing cardiovascular risk by improving lipid profile and offering additional benefits of anti-inflammatory and anti-oxidant effects.